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Abstract
Background: Alzheimer's disease is multifactorial, having environmental, toxicological and genetic
risk factors. Impaired folate and homocysteine metabolism has been hypothesised to increase risk.
In addition to its xenobiotic-metabolising capacity, human arylamine N-acetyltransferase type-1
(NAT1) acetylates the folate catabolite para-aminobenzoylglutamate and is implicated in folate
metabolism. The purpose of this study was to determine whether polymorphisms in the human
NAT genes influence susceptibility to Alzheimer's disease.
Methods: Elderly individuals with and without Alzheimer's disease were genotyped at the
polymorphic NAT1 (147 cases; 111 controls) and NAT2 (45 cases; 63 controls) loci by polymerase
chain reaction-restriction fragment length polymorphism, and the genotype and allele frequencies
were compared using the chi-squared test.
Results: Although a trend towards fast NAT2 acetylator-associated Alzheimer's disease
susceptibility was indicated and the NAT1*10/1*10 genotype was observed only in cases of
Alzheimer's disease (6/147, 4.1%), no significant difference in the frequency of NAT2 (p = 0.835) or
NAT1 (p = 0.371) genotypes was observed between cases and controls. In addition, a novel NAT1
variant, NAT1*11B, was identified.
Conclusions: These results suggest that genetic polymorphisms in NAT1 and NAT2 do not
influence susceptibility to Alzheimer's disease, although the increase in frequency of the NAT1*10
allele in Alzheimer's disease is worthy of further investigation. Due to its similarity with the
NAT1*11A allele, NAT1*11B is likely to encode an enzyme with reduced NAT1 activity.
Background
Alzheimer's disease (AD) is a common multifactorial dis-
ease of the elderly, which results in progressive neurode-
generation causing severe and permanent cognitive
impairment [1]. As a result of family pedigree analyses
and case-control studies, multiple genetic risk factors such
as mutations in the β-amyloid precursor protein (APP)
[2], presenilin type-1 (PS1) [3], presenilin type-2 (PS2) [4]
and apolipoprotein E (APOE) [5] genes have been identi-
fied. Genetic epidemiology studies have however, esti-
mated that only 30% to 50% of the population risk for AD
can be attributed to genetic factors [6]. This along with the
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twins [7,8] suggests that environmental factors may also
influence AD susceptibility. This may be the case particu-
larly for later-onset 'sporadic' cases of the disease, which
account for the majority (approximately 90%) of AD cases
but show only modest familial clustering [6].
Many putative environmental risk factors for AD have
been proposed. In particular, low blood levels of folate
and elevated serum total homocysteine have been associ-
ated with increased risk of AD [9-11]. Differences in the
level of serum homocysteine and folate were not associ-
ated with increasing duration of the symptoms of AD
[10], which suggests that the observed level of these bio-
chemical markers was not due to progression of the dis-
ease. Therefore, impaired folate and homocysteine (one-
carbon) metabolism has been hypothesised as a risk fac-
tor in AD [10]. Such altered folate and homocysteine
metabolism could arise as a result of genetic mutations in
enzymes of folate metabolism.
The association between impaired folate and homo-
cysteine metabolism and AD is particularly interesting in
view of the putative endogenous role of the human phase
II xenobiotic-metabolising enzyme arylamine N-acetyl-
transferase type-1 (NAT1)(and its murine homologue
NAT2), in folate catabolism [12-15], and our previous
demonstration of the expression of murine NAT2 in par-
ticular cell types, such as the cytoplasm and dendrites of
the Purkinjie cells of the cerebellum in the adult mouse
brain [16]. There has as yet been no description of the pat-
tern of human NAT1 expression in the adult brain,
although human NAT1 (the human equivalent of murine
NAT2) activity has been identified in the brain early in
embryonic development [17]. Human NAT1 is polymor-
phic [18] and inter-individual variation in NAT1 activity
[19] may modulate individual folate levels. NAT1 may
therefore be a potential low penetrance gene which can
modify individual risk of AD.
Polymorphisms in the arylamine N-acetyltransferase type-
2 (NAT2) gene, which encodes the phase II xenobiotic-
metabolising isozyme NAT2, have been linked with
increased susceptibility to multifactorial neurodegenera-
tive disorders such as Parkinson's disease [20,21]. In this
case the impaired ability of the individual to handle envi-
ronmental xenobiotics or neurotoxins acting on the brain
has been hypothesised to contribute to the development
of the disease. In a similar manner human NAT2, and in
addition human NAT1, in their more traditionally recog-
nized role as phase II xenobiotic-metabolising enzymes
[22], may also be modulators of AD risk as a result of
chemical insult. An association study carried out by Rocha
et al., [23] has previously indicated that human NAT2
may be a potential low penetrance gene in AD pathogen-
esis. In view of these findings we undertook a study to
genotype an elderly group of individuals with and with-
out a history of AD for major alleles at the NAT1 and
NAT2 loci, to investigate the role of NAT1 and NAT2 pol-
ymorphisms in AD susceptibility.
Methods
Study populations
Genomic DNA from 148 elderly Caucasian individuals
with AD and 90 elderly Caucasian individuals without
AD, from the Oxford Project to Investigate Memory and
Ageing (OPTIMA) cohort, was available for investigation.
OPTIMA is a longitudinal study of normal, non-institu-
tionalised elderly volunteers with good cognitive func-
tion, and elderly patients with memory problems from
the Oxfordshire community (UK), and has been described
in detail elsewhere [10,24]. Briefly, the OPTIMA study fol-
lows the AD course of an individual, from initial diagno-
sis to post mortem confirmation. Every year each subject is
examined by neurological and neuropsychological tests,
brain scans and biochemical analysis of blood and cere-
brospinal fluid. Cognitive evaluation is undertaken using
the Cambridge Examination for Mental Disorders of the
Elderly [25]. This includes the Cambridge Cognitive
Examination (CAMCOG), a neuropsychological test
which includes elements of the Mini-Mental State Exami-
nation and assesses a broad range of cognitive functions,
such as memory, language, attention, perception, praxis
and thinking. A cut-off value of <80/107 CAMCOG points
discriminates between demented and normal subjects.
Clinical diagnosis is made according to the National Insti-
tute of Neurological and Communicative Disorders and
Stroke-Alzheimer's Disease and Related Disorders Associ-
ation criteria [1]. Post mortem, the brain is examined by
histochemical and biochemical methods to confirm dis-
ease pathology using Consortium to Establish a Registry
for Alzheimer's Disease criteria [26]. In this study the AD
case individuals from the OPTIMA cohort included: 101
living patients with a clinical diagnosis of probable or
possible AD, 30 patients with histologically confirmed
pure AD with the absence of any additional disease
pathology, 16 patients with histologically confirmed AD
with the coexistence of vascular or Parkinson's disease
pathology and 1 patient who demonstrated clinical symp-
toms of AD which were not confirmed post mortem. The
non-demented control individuals from the OPTIMA
cohort included: 83 living subjects with no clinically diag-
nosed symptoms of AD, 4 subjects with the absence of AD
confirmed post mortem and 3 subjects who demonstrated
no symptoms of AD which was not confirmed post mor-
tem. The OPTIMA study had ethical approval from the
central Oxford and Psychiatric Research Ethics Commit-
tees and informed consent was obtained in writing from
all subjects.Page 2 of 9
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sight Challenge cohort was also available for investiga-
tion. Foresight Challenge is a cohort of normal, non-
institutionalised elderly volunteers with good cognitive
function from the Oxfordshire community (UK)(non-
black and Caucasian), recruited for a three-year longitudi-
nal study aimed at further defining early markers or pre-
dictors of cognitive impairment and their relationship to
the subsequent development of dementia [27]. Partici-
pants were excluded if they: (a) scored ≤80/107 points on
the CAMCOG or ≤24/30 points on the Mini-Mental State
Examinations [25] at the initial screening visit, (b)
reported significant progressive subjective memory com-
plaints, (c) lived in institutional care, or (d) were unable
to complete the Cambridge Examination for Mental Dis-
orders of the Elderly [25]. For the purpose of this study the
individuals in the case and control groups were regarded
as homogeneous groups. Subjects with other causes of
dementia were excluded from the study.
Materials
All chemicals were purchased from Sigma-Aldrich Com-
pany Ltd., Merck Ltd. or BDH Laboratory Supplies, UK.
Molecular biology reagents were purchased from
Promega, Roche Molecular Biochemicals and New Eng-
land Biolabs Inc., UK. Oligonucleotides were synthesized
by Sigma-Genosys Ltd., UK.
DNA extraction
Genomic DNA from each AD case (n = 148) and control
(n = 90) subject in the OPTIMA cohort, and from each
control subject (n = 22) in the Foresight Challenge cohort
was prepared from the buffy coat fraction of EDTA blood
[28] using the Wizard® Genomic DNA Purification Kit
(Promega, UK), and was stored at 4°C in TE buffer (10
mM Tris-HCl (pH 7.5), 1 mM Na2EDTA).
NAT1 genotyping
The human NAT1*3, NAT1*4, NAT1*10, NAT1*11A and
NAT1*14A alleles (those unfamiliar with NAT allele
nomenclature should see http://www.louisville.edu/med
school/pharmacology/NAT.html) were identified by the
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) and allele-specific PCR (AS-
PCR) step-by-step genotyping procedure [29]. To summa-
rise, a fragment of 344 bp between nucleotides 769 and
1113 was amplified with primers N769 (5'-ACTCTGAGT-
GAGGTAGAAATA-3') and N1113 (5'-ACAGGCCATCTT-
TAGAA-3'). As a result of Mbo II sites at nucleotides 945
and 969, the alleles NAT1*3, NAT1*10 and NAT1*14A
produce fragments of 176 bp, 24 bp and 144 bp on diges-
tion with Mbo II (for NAT1*11A, as a result of a 9 bp dele-
tion, the fragments are 176 bp, 24 bp and 135 bp). The
primer N1113 introduces an additional Mbo II site into
NAT1*4 such that the 144 bp fragment is cleaved to 125
bp and 19 bp. Subsequently, NAT1*3 was distinguished
from NAT1*10 and NAT1*14A by an allele-specific PCR.
NAT1*10 and NAT1*14A were distinguished by a further
PCR and digestion with BsaO I [29]. Nucleotides which
are changed from the NAT1*4 sequence (EMBL Accession
Number AJ307007) are underlined.
The NAT1*14A allele (G560A, T1088A, C1095A) was
confirmed and distinguished from the similar NAT1*14B
allele (G560A), by further analysis using AS-PCR and
nested PCR-RFLP. This analysis first amplified only
NAT1*10 and NAT1*14A allele sequences, and then iden-
tified whether the G560A variation was present. AS-PCR
amplification was performed in a 100 µl reaction using 1X
PCR reaction buffer, 250 ng genomic DNA, 2.5 mM
MgCl2 0.2 mM dNTPs, 2.5 U Taq DNA polymerase and 25
pmoles each of primers N539 (5'-TCCTAGAAGACAG-
CAACGACC-3') and N1110b (5'-GGCCATCTTTAAAATA-
CATTTT-3')(with annealing temperature 54°C and a
product extension of 1 minute at 72°C). Primer N1110b,
which contains T1088 annealed to and amplified a 571
bp product from the NAT1*10 and NAT1*14A allele
sequences only. The PCR product from the first round of
amplification was diluted 1 in 20, and 1 µl used as tem-
plate in a PCR with primers N539 and N714 (5'-
GTGAAGCCCACCAAACAG-3'), followed by BsaO I diges-
tion of the 175 bp amplified product [29]. NAT1*14A
contains G560A; therefore no BsaO I site was generated.
NAT1*10 contains G560, therefore a BsaO I site was gen-
erated resulting in fragments of 155 bp and 20 bp.
NAT2 genotyping
The human NAT2*4, NAT2*5A, NAT2*5B, NAT2*5C,
NAT2*6A and NAT2*7B alleles were identified by geno-
typing using the PCR-RFLP method of Hickman & Sim
[30], and Hickman et al. [31]. This method is more than
95% accurate at predicting the NAT2 phenotype in a Cau-
casian population [31]. This method of genotyping is
unable to distinguish between the NAT2*4/NAT2*5B and
the NAT2*5A/NAT2*5C genotypes. However, since the
expected frequency of the NAT2*4 (19% to 27%) and
NAT2*5B (38% to 45%) alleles in a Caucasian popula-
tion is much greater than the expected frequency of the
NAT2*5A (1.0% to 4.2%) and NAT2*5C (1.0% to 4.3%)
alleles [32], this method is sufficient to confer an accurate
genotype in greater than 99% of cases if the NAT2*4/
NAT2*5B genotype is inferred. Genotyping of both NAT1
and NAT2 was carried out blind with respect to the disease
status of the subjects.
Sequencing of novel NAT1 variant
PCR amplification of a 1614 nucleotide region of NAT1
for cloning and sequencing of a NAT1 variant was per-
formed in a 100 µl reaction using 1 µg genomic DNA, 2.5
U high-fidelity Pfu DNA Polymerase (Promega, UK), 1XPage 3 of 9
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0.2 mM dNTPs, and 25 pmoles each of primers N-438 (5'-
TTGTATAAGGCTCAGCTAAAAGGG-3') and N1176 (5'-
GGAATTCAACAATAAACCAACAT-3')(with annealing
temperature 56°C and a product extension of 2 minutes
at 72°C). Following gel purification, the amplified PCR
product was A-tailed with dATP, ligated into the pGEM®-T
Easy Vector (Promega, UK), and transformed into high
efficiency JM109 Competent E. coli cells (Promega, UK)
by heat shock. Positive clones were identified by blue-
white selection on LB agar plates containing 100 µg/ml
ampicillin, 0.1 mM isopropyl-β-D-thiogalactoside (Mel-
ford Laboratories Ltd., UK) and 40 µg/ml X-Gal. The iden-
tity of the cloned NAT1 sequence was confirmed by NAT1
genotyping of plasmid DNA. The cloned NAT1 inserts
(two different clones for each allele) were sequenced
using M13F (5'-AGGGTTTTCCCAGTCACGA-3') and
M13R (5'-ACACAGGAAACAGCTATGAC-3') sequencing
primers, and the NAT1-specific primer N714. Fluorescent
DNA sequencing was performed by the DNA Sequencing
Facility, Department of Biochemistry, University of
Oxford, using an ABI 377XL Prism DNA Sequencer with
ABI BigDye™ terminators (Warrington, UK). Sequencing
chromatograms were analysed using Chromas version
1.45 (Conor McCarthy, Griffith University, Australia).
Statistical analysis
NAT allele and genotype frequencies for the AD case and
control groups were calculated and the NAT genotype dis-
tribution for AD case and control groups was tested for
Hardy-Weinberg equilibrium. Any deviations from this
equilibrium were assessed using a chi-squared test. NAT
allele and genotype distributions of the AD case and con-
trol groups were compared using the chi-squared test, and
p values of less than 0.05 were considered to be signifi-
cant. The strength of association between inheritance of a
particular NAT allele or genotype and AD was assessed by
calculation of crude odds ratios (OR) and 95% confidence
intervals (CI).
Results
The NAT1 genotype of each individual in the Alzheimer's
case group (n = 147) and the control group (n = 111) was
determined and the frequency of NAT1 alleles and NAT1
genotypes is illustrated in Table 1 and Table 2 respectively.
The distribution of alleles demonstrates that NAT1*4 is
the most common allele in both groups (75–79%), whilst
NAT1*10 is the next most frequent (15–19%). The same
pattern has been observed in all Caucasian populations
that have been studied [32]. The genotypes observed were
determined to be in Hardy-Weinberg equilibrium.
Table 1: NAT1 allele frequency in AD cases and controls.
NAT1 ALLELE AD CASES (N = 147) CONTROLS (N = 111) OR (95% CI)
1*4 220 (0.75) 176 (0.79) 1.00
1*3 9 (0.03) 7 (0.03) 1.03 (0.38, 2.82)
1*10 57 (0.19) 33 (0.15) 1.38 (0.86, 2.22)
1*11A 3 (0.01) 2 (0.01) 1.20 (0.20, 7.26)
1*14A 5 (0.02) 4 (0.02) 1.00 (0.27, 3.78)
TOTAL 294 (1.00) 222 (1.00) -
The number and frequency (in brackets) of NAT1 alleles in 147 AD cases and 111 controls is shown. The OR of AD to non-disease is given with 
95% CI for each NAT1 allele (with NAT1*4 as the reference group).
Table 2: NAT1 genotype frequency in AD cases and controls.
NAT1 GENOTYPE AD CASES (N = 147) CONTROLS (N = 111) EXPECTED OR (95% CI)
1*4/1*4 81 (0.55) 65 (0.59) 0.63 1.00
1*4/1*10 43 (0.29) 33 (0.30) 0.24 1.05 (0.60, 1.83)
1*4/1*3 7 (0.05) 7 (0.06) 0.05 0.80 (0.27, 2.40)
1*4/1*14A 5 (0.03) 4 (0.04) 0.03 1.00 (0.26, 3.89)
1*4/1*11A 3 (0.02) 2 (0.02) 0.01 1.20 (0.20, 7.42)
1*10/1*10 6 (0.04) 0 (0) 0.02 -
1*3/1*10 2 (0.01) 0 (0) 0.01 -
Others 0 (0) 0 (0) 0.01 -
TOTAL 147 (1.00) 111 (1.00) 1.00 -
The number and frequency (in brackets) of NAT1 genotypes in 147 AD cases and 111 controls is shown. Expected genotype frequency was 
calculated based on the allele frequency in the control group (Table 1). 'Others' includes additional NAT1 genotypes containing the alleles 1*4, 1*3, 
1*10, 1*11A and 1*14A expected at low frequency which were not observed in these AD cases and controls. The OR of AD to non-disease is given 
with 95% CI for each NAT1 genotype (with NAT1*4/NAT1*4 as the reference group).Page 4 of 9
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being investigated demonstrates that the allele and geno-
type frequency of the two groups does not differ signifi-
cantly (χ2 = 1.84, p = 0.765 and χ2 = 6.48, p = 0.371
respectively) the number of NAT1*10 alleles is slightly
elevated in the Alzheimer's patient population. Compar-
ing the NAT1*10 homozygote genotype frequency, there
are 6 out of 147 Alzheimer's cases with this genotype,
whilst there are no control individuals with this genotype
out of 111 investigated. Although the numbers are small,
it is a finding worthy of further investigation, especially
since the NAT1*10 allele may have an effect on the level
of NAT1 expression [33].
NAT2 genotyping was carried out on a random subgroup
of the AD cases (n = 45) and of the controls (n = 63). The
frequency of NAT2 alleles and NAT2 genotypes (which
were in Hardy-Weinberg equilibrium) is illustrated in
Table 3 and Table 4 respectively. NAT2*5B is the most
common allele in both groups (39–42%), whilst
NAT2*6A is the next most frequent allele (31–36%), as
seen in other Caucasian populations that have been
studied [32]. A direct chi-squared comparison of the
NAT2 allele and genotype frequencies in the Alzheimer's
case and control groups indicates that they are not signif-
icantly different (χ2 = 1.95, p = 0.857 and χ2 = 5.76, p =
0.835 respectively). In a Caucasian population, an indi-
vidual's NAT2 phenotype can be predicted quite accu-
rately (in more than 95% of cases) by their NAT2
genotype [31]. Therefore the Alzheimer's cases and con-
trol individuals were classified as fast or slow acetylators
and compared (Table 5). Although a small increase in the
frequency of the NAT2 fast acetylator phenotype was
observed in the AD cases (38%) compared with the con-
trols (35%), which is in agreement with a similar study
carried out in a Portuguese sporadic AD population by
Rocha et al. [23], once again no significant difference
between the Alzheimer's case and control group was
observed (χ2 = 0.09, p = 0.761). Other studies have also
demonstrated a lack of association between the NAT2
acetylator phenotype and risk of AD including those by
Steventon et al. [34] and Ladero et al. [35]. However, in
these cases it has been suggested that administration of
therapeutic agents such as tacrine, an acetylcholinesterase
inhibitor used in the treatment of AD, which is thought to
be metabolised by CYP1A2 [36,37] may have affected the
acetylation of sulphamethazine which was used to pheno-
type NAT2.
Discussion
It is hypothesized that variation in NAT1 activity may alter
the risk of AD (which has been associated with low blood
folate levels [9-11]), via the postulated role of NAT1 in
folate metabolism. Together, the results of the present
study suggest that genetic polymorphisms in NAT1 and
NAT2 do not influence susceptibility to AD. It should be
noted that the study presented here is preliminary and its
statistical power is limited due to the relatively small
number of samples analysed, particularly the study of
NAT2 genotype and risk of AD. Therefore much larger
case-control investigations, using more highly automated
detection methods such as the LightCycler real-time PCR
methods of Blömeke et al. [38] and Wikman et al. [39]
will help to validate the results shown here. In order to
detect a 1.5 fold increased risk of AD associated with the
NAT1*10 allele, approximately 650 cases and 650 con-
trols would need to be studied to give 80% power of
achieving significance at the 5% level. Similarly, in order
to detect a 1.5 fold increased risk of AD associated with
the NAT2*4 allele, approximately 520 cases and 520 con-
trols would need to be studied.
It is hypothesised that expression of a high activity NAT2
enzyme might increase the metabolic activation of envi-
ronmental compounds (including neurotoxins), contrib-
uting to the neuronal tissue degeneration characteristic of
AD. However, as no environmental compounds or neuro-
toxins currently suspected of contributing to the develop-
ment of AD are known to be metabolised by the NAT
enzymes, the identification of endogenous NAT substrates
Table 3: NAT2 allele frequency in AD cases and controls.
NAT2 ALLELE AD CASES (N = 45) CONTROLS (N = 63) OR (95% CI)
2*4 20 (0.22) 26 (0.21) 1.00
2*5A 1 (0.01) 4 (0.03) 0.33 (0.03, 3.14)
2*5B 35 (0.39) 53 (0.42) 0.86 (0.42, 1.77)
2*5C 1 (0.01) 2 (0.02) 0.65 (0.06, 7.69)
2*6A 32 (0.36) 39 (0.31) 1.07 (0.51, 2.25)
2*7B 1 (0.01) 2 (0.02) 0.65 (0.06, 7.69)
TOTAL 90 (1.00) 126 (1.00) -
The number and frequency (in brackets) of NAT2 alleles in 45 AD cases and 63 controls is shown. The OR of AD to non-disease is given with 95% 
CI for each NAT2 allele (with NAT2*4 as the reference group).Page 5 of 9
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derivatives, will be important to strengthen the hypothesis
that NAT1 and NAT2 may be risk factors for AD as a result
of chemical insult.
At present, the suggestion for an endogenous role for
human NAT1 has focused on the ability of human NAT1
to acetylate the folate catabolite para-aminobenzoylgluta-
mate [12,13]. However, it is possible that NAT1 may play
a role in the metabolism of other, as yet unidentified
arylamines. Experiments in which the murine gene equiv-
alent to human NAT1 (murine NAT2) has been knocked
out indicate that superficially the mice are well [40]. How-
ever, in view of the distribution of murine NAT2 in the
nervous system [16], it is important that subtle tests
involving behaviour are carried out and the histology of
the nervous system is studied in order to determine the
role of murine NAT2 in the nervous system and identify
whether there might be compensating factors at play in
the genetically modified mice. In addition, mice over-
expressing the human NAT1 gene show developmental
abnormalities [41].
Whilst identifying the NAT1 alleles, a pattern was
observed in one individual that was not consistent with
any known NAT1 genotype. Only individuals with the
NAT1*4 allele generate restriction fragments of 176 bp
and 125 bp following PCR amplification of the region
corresponding to nucleotides 769 to 1113, and digestion
with the restriction enzyme Mbo II. This allele (NAT1*4)
is present in the individual indicated by the open arrow in
Figure 1(a). However, most other known NAT1 alleles (in
which the primer N1113 does not generate an additional
Mbo II restriction site) generate fragments of 176 bp and
144 bp, apart from NAT1*11, in which the corresponding
fragment is 135 bp due to a 9 base pair deletion. In the
case of the individual identified by the open arrow, an
additional band of 116 bp was identified which was not
Table 4: NAT2 genotype frequency in AD cases and controls.
NAT2 GENOTYPE AD CASES (N = 45) CONTROLS (N = 63) EXPECTED OR (95% CI)
2*4/2*4 3 (0.07) 4 (0.06) 0.04 1.00
2*4/2*5A 1 (0.02) 4 (0.06) 0.01 0.33 (0.02, 4.74)
2*4/2*5B 6 (0.13) 10 (0.16) 0.17 0.80 (0.13, 4.87)
2*4/2*6A 6 (0.13) 4 (0.06) 0.13 2.00 (0.28, 14.20)
2*4/2*7B 1 (0.02) 0 (0) 0.01 -
2*5B/2*5B 6 (0.13) 8 (0.13) 0.18 1.00 (0.16, 6.26)
2*5B/2*5C 1 (0.02) 1 (0.02) 0.01 1.33 (0.06, 31.12)
2*5B/2*6A 16 (0.36) 25 (0.40) 0.26 0.85 (0.17, 4.33)
2*6A/2*6A 5 (0.11) 5 (0.08) 0.10 1.33 (0.19, 9.31)
2*5B/2*7B 0 (0) 1 (0.02) 0.01 -
2*5C/2*7B 0 (0) 1 (0.02) 0.00 -
Others 0 (0) 0 (0) 0.08 -
TOTAL 45 (1.00) 63 (1.00) 1.00 -
The number and frequency (in brackets) of NAT2 genotypes in 45 AD cases and 63 controls is shown. Expected genotype frequency was calculated 
based on the allele frequency in the control group (Table 3). 'Others' includes additional NAT2 genotypes containing the alleles 2*4, 2*5A, 2*5B, 
2*5C, 2*6A and 2*7B expected at low frequency which were not observed in these AD cases and controls. The OR of AD to non-disease is given 
with 95% CI for each NAT2 genotype (with NAT2*4/NAT2*4 as the reference group).
Table 5: NAT2 phenotype distribution in AD cases and controls.
NAT2 PHENOTYPE AD CASES (N = 45) CONTROLS (N = 63) OR (95% CI)
fast acetylator 17 (0.38) 22 (0.35) 1.00
slow acetylator 28 (0.62) 41 (0.65) 0.88 (0.40, 1.96)
TOTAL 45 (1.00) 63 (1.00) -
The number and frequency (in brackets) of fast and slow NAT2 acetylators in 45 AD cases and 63 controls is shown. Based on their genotype, AD 
cases and controls were classified as either 'fast' or 'slow' NAT2 acetylators. Individuals homozygous or heterozygous for the NAT2*4 allele were 
assigned fast NAT2 acetylators, individuals who carried two 'slow' NAT2 alleles (NAT2*5A, NAT2*5B, NAT2*5C, NAT2*6A and NAT2*7B) in any 
combination were assigned slow NAT2 acetylators [31]. The OR of AD to non-disease is given with 95% CI for each NAT2 phenotype (with NAT2 
fast acetylator as the reference group).Page 6 of 9
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whether this restriction pattern was due to the presence of
a novel allele, the NAT1 alleles (a 1.6 Kb region) from the
individual were cloned and sequenced. As a result, a novel
allele was identified and defined as NAT1*11B (with C at
1095) due to its high sequence similarity with NAT1*11A
(with A at 1095) (Figure 1(b)). NAT1*11B contains six
mutations with respect to the NAT1*4 sequence: C-344T,
A-40T, G445A (V149I), G459A, T640G (S214A), 9 bp
deletion in the nucleotide region 1065–1090. The func-
tional consequences of this allele are likely to be similar to
that of NAT1*11A where an association with low enzymic
activity has been proposed as a result of the amino acid
changes V149I and S214A [42,43]. Other changes in the
novel allele compared with NAT1*4 are outside the cod-
ing region (Figure 1(b)) and their effects have not yet been
Identification of a novel NAT1 alleleFigure 1
Identification of a novel NAT1 allele. (a) A 344 bp PCR product of NAT1 (amplified from genomic DNA using primers N769 and 
N1113, the latter introducing an additional Mbo II restriction site in NAT1*4) was digested with Mbo II and separated on a 4% 
(w/v) MetaPhor® agarose (FMC BioProducts, UK)/0.5X TBE gel, against a 1 kb DNA Ladder (Gibco BRL, UK)(Lane M). Detect-
able NAT1*4 fragments are 176 bp and 125 bp. Fragments of other known alleles are 176 bp and 144 bp (NAT1*3, NAT1*10, 
NAT1*14A) or 176 bp and 135 bp (NAT1*11A). The individual marked with an open arrow had a novel restriction fragment 
(116 bp) which did not correspond to any known allelic combination. (b) Both NAT1 alleles of the individual marked with an 
open arrow were sequenced across the coding and 5' and 3' flanking regions and the sequence of the novel allele (NAT1*11B) 
is illustrated in comparison with the most common Caucasian NAT1 allele, NAT1*4 (EMBL Accession Number AJ307007) and 
the most similar NAT1 allele, NAT1*11A. NAT1*11B contains sequence variations identical to those of NAT1*11A (C-344T, A-
40T, G445A, G459A, T640G and a 9 base deletion (∆) in the nucleotide range 1065–1090, compared with the NAT1*4 
sequence), but contains a cytosine at nucleotide 1095. The 870 bp coding region of NAT1 is shaded grey, with 438 nucleotides 
upstream and 306 nucleotides downstream also shown.
     C              A                                           G   G                     T                                                               C
  T               T                                           A   A                    G                                                     ∆9      A
  T               T                                           A   A                    G                                     ∆9      C
NAT1*4
NAT1*11A
NAT1*11B
-344           -40                                        445 459                640                                        1065-1090   1095
(a)
(b)
176 bp
  144 bp
  125 bp
  116 bp
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BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/6established. Although this allele was identified in an AD
patient, it is unlikely to play a significant role in the patho-
genesis of AD since it was found in only one individual.
Conclusions
In conclusion, the study presented here, which to our
knowledge includes the first known investigation of the
association between NAT1 genotype and susceptibility to
AD, suggests that genetic polymorphisms in NAT1 and
NAT2 do not influence susceptibility to AD. However, the
inclusion of SNP analysis at positions 1088 and 1095 in a
multi-variant analysis would be warranted based on the
present studies since there is an indication that NAT 1*10
is elevated in AD.
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